Tracking Chemotherapy Effects via ALDH1A1, SOX2, CD44v6, and P-gp Expression in Malignant Ascites from High-Grade Serous Carcinoma
Pathobiology · 27.04.2026 · 1-13
DOI: 10.1159/000551677 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathobiology, online erschienen am 27.04.2026. Verfasst von Mariana O Nunes und 9 weiteren Autor:innen. Beteiligte Einrichtung: Differentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto, Institute of Molecular Pathology …. Die Arbeit nennt 45 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Malignant ascites is frequently observed in high-grade serous carcinoma (HGSC), yet its value as a dynamic source for molecular profiling across treatment stages remains underexplored. The main aim of this study was to evaluate the feasibility of immunocytochemical analysis of malignant ascites (MA) samples from patients with high-grade serous carcinoma. A goal was to determine whether marker expression varies before and after chemotherapy and between clinical response groups.
Methods
A cohort of 37 MA samples from 33 HGSC patients was analysed by immunocytochemistry for ALDH1A1, SOX2, CD44v6, and P-glycoprotein. Full-volume centrifugation of MA (1–4 L) was used to maximize tumour cell recovery. A biomarker profile was considered positive if ≥1 marker showed >10% tumour cell expression.
Results
This profile was significantly more frequent in post-chemotherapy samples (72.2%) than in pre-chemotherapy samples (21.1%; p = 0.003). Stratified analysis revealed increased expression in platinum-sensitive patients following chemotherapy (60% vs. 14.3%, p = 0.032), suggesting chemotherapy-induced reprogramming rather than selection alone. Expression of p-glycoprotein was more frequent in resistant cases, though often limited to
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Differentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto, Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal.
- Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal.
- Applied Molecular Biosciences Unit (UCIBIO), Toxicologic Pathology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), Gandra, Portugal.
- Associate Laboratory i4HB, Institute for Health and Bioeconomy, University Institute of Health Sciences (IUCS), University Polytechnic Higher Education Cooperative (CESPU), CRL, Gandra, Portugal.
- Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal.
- Department of Medical Oncology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal.
Zitieren
APA
Nunes, M. O., Almeida-Nunes, D. L., de Lima, A. E. C., Ferreira, V., Lobo, C., Monteiro, P. M., Carvalho, S., Abreu, M. H., Bartosch, C., & Ricardo, S. (2026). Tracking Chemotherapy Effects via ALDH1A1, SOX2, CD44v6, and P-gp Expression in Malignant Ascites from High-Grade Serous Carcinoma. Pathobiology, 1-13. https://doi.org/10.1159/000551677
Vancouver
Nunes MO, Almeida-Nunes DL, de Lima AEC, Ferreira V, Lobo C, Monteiro PM, et al. Tracking Chemotherapy Effects via ALDH1A1, SOX2, CD44v6, and P-gp Expression in Malignant Ascites from High-Grade Serous Carcinoma. Pathobiology. 2026:1-13. doi:10.1159/000551677
BibTeX
@article{Nunes2026,
author = {Nunes, Mariana O and Almeida-Nunes, Diana Luísa and de Lima, Ana E C and Ferreira, Verónica and Lobo, Cláudia and Monteiro, Paula M and Carvalho, Sara and Abreu, Miguel Henriques and Bartosch, Carla and Ricardo, Sara},
title = {Tracking Chemotherapy Effects via ALDH1A1, SOX2, CD44v6, and P-gp Expression in Malignant Ascites from High-Grade Serous Carcinoma},
journal = {Pathobiology},
year = {2026},
pages = {1--13},
doi = {10.1159/000551677}
}
EUVIMED